Exicure assigns GPC-100 program to GPCR Therapeutics USA
On November 30, 2026, Exicure, Inc. agreed to sell and assign assets related to the GPC-100 program to GPCR Therapeutics USA Inc. The deal aims to transfer obligations and IP known as Burixafor, following the acquisition of GPCR USA.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed